The cardiovascular outcomes trial SUSTAIN-6, published in the New England Journal of Medicine, demonstrated cardiovascular safety in a population where many participants were receiving antiplatelet therapy
White 2,625 views 4 faves 2 comments Uploaded on December 27, 2009 Taken on December 27, 2009 Ian White By: Ian White Comb Duck (Sarkidiornis melanotos) 2,625 views 4 faves 2 comments Uploaded on December 27, 2009 Taken on December 27, 2009 All rights reserved
Binvignat, M., Sellam, J., Berenbaum, F
Use in Patients with Liver Disease: Ondansetron is primarily metabolized by the liver, so caution is advised when prescribing this medication to individuals with severe liver impairment
Abcam) according to the manufacturers instructions